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Abstract:
Objective: the off-label use, referring to the applicabil-
ity of pharmaceutical drugs beyond the submitted and
from the federal Institute for Drugs and Medical De-
vices (BfarM, Bundesamt f￼r arzneimittel und Mediz-
inprodukte) certified and approved administration, is
the subject of controversial discussions. the applica-
tion can be considered in case of severe illness - if no
therapeutic alternatives are available - or it exists as a
founded perspective for achieving therapeutic success. 
Methods: a latitudinal study for evaluating the applica-
tion of off-label use supplements was performed at 43
German  university  and  academic  teaching  hospitals.
five doctors at each hospital applied off-label pharma-
ceutical drugs and were called upon to share their per-
sonal experience to the application of those medica-
tions.  
Results: 75 (35%) questionnaires were returned out of
22 (51%) medical centres with 215 contacted physi-
cians. Off-label use was common for 65 (91%) of the
physicians. Only 9% of them obviate the application
of off-label drugs. about a half of the medication is
related to application in obstetrics (54%) and in most
cases on an every day basis. Uterotonics were the most
commonly  used  off-label  medications  (34%).  the
main part of information about off-label use is ob-
tained from personal information of colleagues (66%)
and  personal  experience  (58%).    34%  of  physicians
think that off label use is risky. Interestingly, the view
about off label use of medication varies considerably
among physicians from various hospitals. 
Conclusions: the application of off-label pharmaceuti-
cal drugs in Germany seems to be a well established
practice. More than 90% of participators of our trial
use at least one medication outside the administration.
this  includes  particularly  prostaglandins,  anti-hyper-
tonic therapeutics and chemotherapeutics.
Key  words: off-label use, federal Institute for Drugs
and Medical Devices (BfarM), Obstetrics and Gynae-
cology
Abbreviations:  BfarM:  Bundesamt  f￼r  arzneimittel
und Medizinprodukte; fDa: food and Drug adminis-
tration; SGB V: Strafgesetzbuch V, Penal Code; BSG:
Bundessozialgericht,  Social  federal  Court;  G-Ba:
Gemeinsamer  Bundesausschu￟,  committee  dealing
with national issues; BGH: Bundesgerichtshof, federal
Court  of  Justice;  BVG:  Bundesverfassungsgericht,
federal  Constitutional  Court;  aMG:  arzneimittelge-
setz, German Medicines Law
IntRODUCtIOn
Just for oncologic indications a multitude of new, in-
novative and expensive drugs was licensed in the last
10 years. Increasingly, every new product development
has to confront economic questions as hurdles. Regu-
latory aspects obtain an important part in this respect,
while the limited indication of administration is based
on studies after initial registration of the drugs [1].
the off-label use (table 1), meaning the applicabili-
ty of pharmaceutical drugs beyond the submitted and
from the federal Institute for Drugs and Medical De-
vices (BfarM, Bundesamt f￼r arzneimittel und Mediz-
inprodukte; USa: fDa: food and Drug administra-
tion) certified and approved administration, is subject
of controversial discussions in circles of various stake-
holders such as health care payers, pharmaceutical in-
dustry, physicians, and patients. 
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Table 1. Off-label use.
Legal consideration  Status of administration Medical requirement
(rechtl. Regelung) in Germany
Pharmaceutical law not regulated;  Permitted in different indication  Life-threatening diseases without 
permitted within therapeutic flexibility  (in Germany) alternative therapeutic option and good 
of the physician, reimbursement in  evidence for therapeutic success
ﾧ35bSGBV
(out of reference 1), SGBV (Sozialgesetzbuch 5): Social Security Code 5
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process requires substantial evidence of efficacy and
safety for specific clinical situations. although off-la-
bel prescribing is legal and common, it is often done
in the absence of adequate supporting data. Off-label
use  has  not  been  formally  evaluated,  and  evidence
provided for one clinical situation may not apply to
others.  In  order  to  increase  awareness  of  off  label
use, public institutions are also becoming active in this
area [2]. 
We hypothyse, that despite risks of litigation off-la-
bel use is common on German University and acade-
mic teaching hospitals.
MatERIaL, MEtHODS anD StatIStICS
from  June  2006  until  June  2007  a  latitudinal  study
evaluating  the  application  of  off-label  use  supple-
ments  was  performed  at  43  German  university  and
academic teaching hospitals – concentrating on the de-
partments of Obstetrics and Gynaecology. five physi-
cians (respectively director, senior assistant medical di-
rector, youngest assistant medical director, senior and
youngest  intern)  of  each  department  were  asked
whether  they  applied  off-label  pharmaceutical  drugs
and about their personal opinion and information to
the application of those medications. 
the questions were divided among 3 main topics.
the first included theoretical and practical experiences
of the participant. 
the second block was specific to the hospital use of
off label medication for individual therapy and the dif-
ferences among participating physicians. 
the third part of the questionnaire referred to the
individual physicians` background and opinion using
off-label medications. 
for the survey, qualitative data were entered into a
SPSS database (version 16.0) and analyzed using SPSS
software and open-ended questions were sorted and
reported by response item.
RESULtS
215 physicians out of 43 German university and acad-
emic  teaching  hospitals  (Department  of  Obstetrics
and  Gynaecology)  were  contacted  twice,  via  letter.
Seventy-five (35%) questionnaires were returned from
22 (51%) medical centres. this included the completed
forms of 14 directors, 29 assistant medical directors
and  28  interns.  four  questionnaires  were  returned
blank, either because no off label use was being per-
formed in that hospital or due to lack of time for an-
swering  the  questionnaire.  thus,  for  analysis  of  the
single questions, 71 (33%) questionnaires could be in-
cluded.
the median professional experience of the partici-
pating physicians was 10 years (+/-SD 10,09, range 1-
36 years).
Within the consulted physicians the professional ex-
perience ranged from 1 year to 36 years. 
Off-label use was common for 65 physicians (91%).
Six  physicians  denied  off-label  use  at  their  hospital.
therefore,  answering  the  single  questions  was  only
possible for 65 of the physicians.
answers  related  to  off-label  use  at  the  individual
hospital are summarized in table 2.
Most  of  the  directors  thought  using  off-label  is
only common for directors, assistant medical directors
and medical specialists (10/13; 77%). However, many
interns  are  convinced  that  off-label  drugs  are  com-
monly  used  by  young  interns  (11/26  interns;  42%)
themselves.
Most of the medications are ordered as hospital-
medication (39/65, 60%).
Rarely, further medications such as anticoagulants
and  immunotherapeutics  were  chosen.  In  obstetrics
the most commonly used off label drugs were: Miso-
prostol, nifedipin, Metformin.
In the case of off label medication use in the field
of obstetrics, a main question was if the use is depen-
dent or independent of gestational age of the patient.
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Table 2. answers related to off-label use at the individual hospital.
Answers Number of physicians (n) Percentage (%)
Kind of physician, who administers  56 (assistant  medical directors) 86
off-label drugs most commonly 24 (interns) 66
(point of physicians view)
frequency of using off-label  31 (daily) 48
medicaments 23 (weekly) 35
11 (rare exception) 17
Kind of procedure  - going along with 
off-label:
-product information 36 55
-technical literature 55 85
-educational advertising 61 94
-none
Most commonly used off-label 
medicaments:
-Uterotonics 22 34
-tocolytics 18 28
-Chemotherapeutics 15 23
2) Ditsch_Umbruchvorlage  14.01.11  12:06  Seite 8thirty-two physicians see a relation between off-label
use and gestional age, especially for the use of Miso-
prostol (in case of incomplete abortion and/or induc-
ing birth at gestional age of 37+0 or above). In case of
nifedipin, the questioned physicians agreed in begin-
ning with the off label use no earlier than the 24th
week of gestation, where viability was guaranteed. In
case of Misoprostol and Indomethacin results showed
inconsistency for gestational weeks as specified in lit-
erature [3, 4]. 
aWaREnESS REGaRDInG LEGaL aSPECtS
Off-label use in Gynaecologic and Obstetric depart-
ments of university and teaching hospitals, according
to  physicians point of view, does not need the accep-
tance of the health insurance company (59/65, 91%),
costs are mostly accepted by health insurance compa-
ny  (54/65,  83%),  is  inside  the  insurance  coverage
(64/65, 98%), is not only allowed within treatment tri-
als (61/65, 94%) and is not considered as a medical
malpractice (65/65, 100%).
there is deep disagreement between the questioned
physicians (37 vs. 29 and 32 vs. 34) as to whether off-
label use should only be permitted by medical special-
ist or only allowed with the consent of the hospital
management.
Most physicians agree about the requirement of ed-
ucational  advertising  and  signed  consent  (60/65,
92%). the off-label use should be dependent on the
indication (55/65, 85%).
KnOWLEDGE
a main part of information about off-label use in gen-
eral  is  obtained  from  personal  information  of  col-
leagues  (42/65,  66%)  and  own  experience  (38/65,
58%). furthermore, information about off-label use is
extracted from technical literature (54/65, 83%) and
medical conventions (41/65, 63%). Half of the physi-
cians get information from product information pro-
vided by the drug producer (33/65, 51%). Only a few
physicians get their information through legal advice
(11/65, 17%) and hardly anybody (5/65, 8%) obtains
it via the internet.
SUBJECtIVE SELf-aSSESSMEnt
the  personal  estimation  of  the  physicians  could  be
classified  as  prohibited,  risky  or  harmless.  22  (34%)
think that off-label use is a risky business, 28 (43%)
consider  it  as  harmless  -  mainly  young  physicians
(65%). there were no significant differences between
single  groups  (directors,  assistant  medical  directors
and interns). But in the group of interns there was a
trend to harmlessness (15/27; 56%). nobody classi-
fied it as prohibited and 15 (23%) out of the 65 physi-
cians abstained from voting.
DISCUSSIOn
Physicians' freedom to prescribe drugs off-label car-
ries  important  advantages.  It  offers  patients  and
physicians earlier access to potentially valuable med-
ication and allows physicians to adopt new practices
based on emerging evidence. It permits innovation in
clinical  practice,  particularly  when  approved  treat-
ments have failed. Off-label use is frequently imple-
mented to reduce costs (e.g. Misoprostol). But off-la-
bel use has potentially negative consequences, as well.
It undercuts expectations that drug safety and efficacy
have been fully evaluated. When newer, more expen-
sive drugs are used off-label, it can lead to increase
health care costs.
Off-label use is common practice in obstetrics and
gynaecology. Our findings support these data. 91% of
the physicians use off-label drugs at regular intervals.
although in most cases medical specialist standard is
required, using off-label drugs in Germany seems to
be often standard for young interns, independent of
their educational background. Interestingly enough al-
though one of the employed physicians in one hospi-
tal referred to off-label use as a common practice for
director, assistant medical director and interns, the di-
rector of the same hospital denied off-label use.
a data collection from Radley et al. showed an esti-
mated 150 million off-label citations (21% of overall
use)  among  the  sampled  medications  in  2001.  Most
off-label drug use (73%) had little or no scientific sup-
port [5]. In contrast to this especially in neonatology
almost all medicatons (up to 90%) are used in off-label
[1]. In order to solve this discrepancy a first step could
be the improvement of the quality of product infor-
mation [2] that currently presents deficient data con-
cerning administration status [6].
Our data show that almost half of the physicians
(43%,  23%  abstained  from  voting)  and  particularly
young  physicians  estimate  off-label  use  as  legal  and
safe. If a patient suffers from an off-label drug, the
only person who can be made liable is the physician
who prescribed the medication – independent of his
standard of knowledge [7, 8]. In most cases personal
liability insurance cover the physician. the questioned
physicians are conscious of this business (98%). ther-
apies are considered as co-insured when approved in
medical  science.  Co-insured  is  the  application  of
drugs, which are outside the permitted indication, if
efficacy and harmlessness are documented in trials but
enlargement of accreditation is not applied or already
accorded [6]. Sole exception from holding liable the
prescribing physician is the joint knowledge of a man-
aging director of the health insurance company if the
latter  rendered  services  without  legal  foundation  or
against applicable enforceable law. In this situation (if
statutory  services  are  exceeded)  the  director  of  the
health insurance company is liable for the costs.  
Eighty-three percent of the physicians expect that
the  incurred  costs  for  off-label  drugs  are  payed  by
health insurance companies. But in principle, the SGB
V (Strafgesetzbuch V, penal code) does not allow pay-
ment for off-label use by public health insurance com-
panies. However, this principle does not imply that the
substance cannot be successfully used or that the pa-
tient has no right to request and receive it. In a 2002
ruling [10] the BSG (Bundessozialgericht, the German
federal social court) made it clear that there are ex-
emptions from this rule and that patients do have the
right to receive off-label drugs in case of:
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- no available alternative treatment; if there is an al-
ternative therapy available or there exists a founded
chance of success, off label use is often insufficient
regardless of the educational background of the in-
volved physician. for answering those questions the
German  cancer  society  (Deutsche  Krebsge-
sellschaft) and medical associations are predestinat-
ed [8],
- potential and/or evident treatment success (phase
III trials) [11, 12]. the danger of insufficient drug
safety in off-label use is considered minimal if the
drug has passed the legally required safety tests [13],
respectively existence of publications with consen-
sus of expected success [14].
after newer opinions for admitting off-label use in-
dividual  risk-benefit-analysis  is  of  particular  impor-
tance [15]. If therapeutic alternatives are missing, fol-
lowing  steps  are  taken  into  consideration  (table  3)
[11].
as a direct result of the 2002 BSG (Bundessozial-
gericht, federal Social Court) ruling, an expert com-
mission was founded at the BfarM (Bundesinstitut f￼r
arzneitmittel und Medizinprodukte, federal Institute
for Pharmaceuticals and Medical Products)  to solve
the disputed off-label use conflict [16, 17]. In case of
missing  comments  of  the  expert  commission  for  a
special drug there is no absolute liability of the drug
producer. there is a new adjudgement of the BVG
(Bundesverfassungsgericht,  federal  Constitutional
Court),  which  is  of  overriding  importance  of  the
BSG: in a life-threatening situation and if alternatives
are missing, off-label drugs could be used and costs
refunded, even though there are weak references for
efficacy [18].
In exceptional case a prescription of off-label drugs
within the pharmaceutical product guideline is possi-
ble by debiting the health insurance company:
1. Positive recommendation of the expert commission
for  application  of  an  off-label  drug  (the  federal
Minister of Health and Social Security has estab-
lished an expert commission to evaluate scientifical-
ly off-label use and provide advice on such practice
[13]),
2. acceptance of this off-label use as conventional use
through pharmaceutical contractor,
3. acceptance of the drug and the off-label indication
in  part  a  of  the  drug  guideline  of  the  G-Ba
(Gemeinsamer Bundesausschu￟, committee dealing
with national issues) [14],
4. a licensed alternative does not exist.
In the board decision of the BSG (Bundessozial-
gericht, federal Social Court) from 2006 for a physi-
cian it is possible not to decide by himself for off-label
drug prescription, but to get a vote of credit from the
accordant health insurance company. In case of de-
cline it is feasible to expose a private prescription [19].
In some cases, only off-label use can guarantee the
legally required treatment according to the newest sci-
entific findings. Current jurisdiction has specified the
conditions for off-label use [13].
In individual cases, it is quite possible that a physi-
cian is even enganged by civil law to use drugs off-la-
bel and in case of acting in opposition to it can be
held liable because of failure to render assistance [20,
21].
the  German  BGH  (Bundesgerichtshof,  federal
Court of Justice) has commented on liability for med-
ical  malpractice  in  a  new  adjudgement  from  March
2007 in an individual treatment attempt [22]: the indi-
vidual treatment attempt with a registration required
but not yet licensed drug is not outlawed and is not yet
an error in treatment. 
the physician has to get active information (of his
own accord) about off-label use [22]. Individual educa-
tion of the patient is most important in using off-label
drugs.  the  questioned  physicians  are  in  accordance
with the existing law. Individual education should be
carried out in detail information with advice for possi-
ble  existence  of  unknown  risks.  the  patient  should
sign the information form like patients in trials [22].
ninety-two percent of the questioned physicians al-
ready follow these judical rules.   
Half  of  the  questioned  physicians  specified  that
they received their information from the industry. the
industry may facilitate off-label use by exploiting areas
of ambiguity where policy is permissive, undefined, or
not enforced. Besides sponsorship of continuing med-
ical education programs, a key promotional strategy is
providing physicians with journal articles about off-la-
bel uses. this practice does educate physicians, but it
is problematic because the trials reported are often of
unclear quality, industry-sponsored, and placebo-con-
trolled (rather than comparisons with approved thera-
pies). In the USa the fDa's recently published draft
guidelines address the distribution of journal articles
by  pharmaceutical  sales  representatives  [23].  the
guidelines suggest a more permissive attitude toward
the  promotion  of  off-label  uses  of  drugs.  though
they carry forward many provisions of the fDa Mod-
ernization act, there are two glaring omissions. first,
manufacturers need no longer limit their promotion of
off-label uses to drugs and indications for which they
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Table 3. Steps of the off-label-use if therapeutic alternatives are missing.
Step Severity of disease Off-label use
1 no severe disease no off-label use
2 Severe disease Off label use in well founded chance of 
success
3 Life-threatening disease Off-label use as well as in lower chance of 
success
(out of reference 11)
2) Ditsch_Umbruchvorlage  14.01.11  12:06  Seite 10are working toward fDa evaluation; and second, there
is  no  requirement  for  advance  fDa  review  of  the
journal articles to be distributed [24]. 
In  contrast  to  off-label  use,  an  unlicensed-use
means  the  application  of  imported  verified  thera-
peutics  aside  from  clinical  studies  without  admitted 
license or modified formulations of registered phar-
maceutics [25, 26]. In the USa the fDa prohibits the
individual  import  of  drugs  which  are  not  licensed
[27].
actually, 83% of the physicians think that costs for
off-label drugs are accepted by health insurance com-
panies, but according to law, the pharmaceutical com-
pany is not engaged. In future, physicians will possibly
not use off-label drugs because of the current major
reimbursement problem of the health insurance com-
pany for the hospital. In Germany, current research
into cost recovery showed that off-label use therapies
are only financially viable until 500 Euro [28].
Currently,  satisfying  drug-legitimate  solutions  are
not available [29]. In Germany, until now the off-label
use  is  not  regulated  neither  from  the  aMG
(arzneimittelgesetz,  German  Medicines  Law),  nor
from Social assistance Law. Our examination showed
discordance of the physicians especially in questions
of liability, reimbursement of costs and personal al-
lowance of prescription - the physician has penal en-
gagements and engagements by civil law (medical spe-
cialist) [12]. Within the asked persons 37% think, that
medical specialist standard is not necessary. this could
implicate legal problems.
Physicians desire the autonomy to prescribe drugs
that match individual patient needs regardless of label,
but  they  face  difficulties  staying  abreast  of  rapidly
evolving evidence. More education to legal status in
using off-label drugs (actually only 17% engaged juris-
tic advice) and cost coverage is necessary. the increas-
ing consolidated medical findings and complexity of
law as concentrated allocation-conflicts of the health
care system will intensify the complexity of problems
with the open questions of the off-label use in the fu-
ture. to be a physician will require basic knowledge in
social law and health care policy. a limitation of pure
medicine won`t be possible, and would no longer be
affordable in future [30].
as main point of this study it can be concluded,
that off-label use is only permitted if there is no li-
censed alternative medication for an ascertained indi-
cation. 
Using  the  example  of  Misoprostol  (licensed  drug
for ulcer therapy) which however in obstetrics lacks a
permitted off-label use the application is solely propa-
gated through cost reduction, since although conven-
tional  prostaglandins  are  available,  they  are  avoided
due to high financial cost. for the most part this point
seems  to  be  the  only  motivation  for  using  off-label
medication. But it has to be constituted clearly, that
Misoprostol use is not covered by off-label use only
for cost-reduction. there does not exist an assump-
tion of costs and legal coverage.
this and the missing absorption of costs through
the health insurance company demonstrate a pulsating
culmination point. Convergence of both sides is de-
manded for an optimal patient-maintenance.
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